Decompensated Cirrhosis

Etiology and Risk Factors

Infection, GI bleeding, diuretic-related volume shifts, sedating drugs, and new kidney injury can precipitate decompensation in a previously stable patient (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Epidemiology and Clinical Context

Population context: Frailty, sarcopenia, comorbidity, and limited access to reassessment increase practical risks after discharge, even when a single prognostic score appears reassuring (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Pathophysiology

Mechanistic cascade: from portal resistance to systemic failure

Fibrosis and regenerative nodules elevate intrahepatic resistance. Portal hypertension drives collateral vessel formation and increased splanchnic vasodilation. The resulting reduction in effective arterial filling activates sympathetic, renin–angiotensin–aldosterone and vasopressin signaling. Sodium and water retention increase ascites and dilutional hyponatremia; progressive renal vasoconstriction can culminate in hepatorenal syndrome-associated acute kidney injury (HRS-AKI). Reduced hepatocyte mass and portosystemic shunting also impair detoxification and alter hemostasis (Damjanovska, 2024; Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Clinical Manifestations

Recognize the syndrome, mechanism and emergency priority

Emergent presentations require immediate stabilization and evaluation for concurrent precipitants (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Diagnostic Evaluation

Ascites: distinguish portal fluid accumulation from infection

Ascites results from a combination of portal hypertension, excessive hepatic lymph formation, systemic arterial vasodilation and neurohormonal sodium retention. The patient may have substantial total-body fluid overload while the kidneys detect inadequate effective arterial filling. New-onset ascites accessible for sampling should undergo diagnostic paracentesis. In cirrhosis with ascites requiring emergency hospitalization, obtain diagnostic paracentesis even when signs of infection are absent. A serum-to-ascites albumin gradient (SAAG) of 1.1 g/dL or greater supports portal hypertensive physiology, but does not establish cirrhosis as the sole cause (Biggins et al., 2021; Mukhtar & Khalili, 2019).

SBP is diagnosed when the ascitic polymorphonuclear leukocyte count is at least 250 cells/mm³ in the relevant clinical setting, including culture-negative neutrocytic ascites. Do not require a positive fluid culture before recognizing or treating suspected SBP. Infection may present as abdominal pain, fever, altered mentation, hypotension or unexplained worsening renal function, and may be minimally symptomatic. Secondary bacterial peritonitis must be reconsidered when the presentation, ascitic studies or response suggests a perforated or surgically treatable source (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Encephalopathy: diagnose clinically and remove precipitants

Hepatic encephalopathy reflects impaired liver detoxification, portosystemic shunting and neuroinflammatory effects that alter cerebral function. The spectrum extends from attention or sleep–wake changes to disorientation, asterixis, stupor and coma. Serum ammonia neither establishes the diagnosis nor reliably stages severity. Search for infection, GI bleeding, constipation, electrolyte disturbance, kidney injury, sedating drugs and other cerebral or metabolic diagnoses. Lactulose lowers intestinal ammonia absorption and rifaximin can be an adjunct in appropriate patients; avoid routine protein restriction because malnutrition and sarcopenia worsen clinical reserve (Bajaj et al., 2026; Mukhtar & Khalili, 2019).

Acute kidney injury: avoid assuming HRS-AKI

HRS-AKI is a kidney-injury phenotype in patients with cirrhosis and ascites. The 2024 ADQI–ICA consensus recognizes a creatinine increase of at least 0.3 mg/dL within 48 hours OR at least 50% from baseline within seven days, and/or urine output of 0.5 mL/kg/hour or less for at least six hours, coupled with lack of improvement within 24 hours after adequate resuscitation when indicated and no stronger alternative cause. Tubular injury or pre-existing CKD does not automatically exclude concurrent HRS. A routine 48-hour albumin challenge is NOT a diagnostic prerequisite. Urgently evaluate bleeding, sepsis, hypovolemia, nephrotoxins and obstruction (Nadim et al., 2024).

Expected Findings

Presentation	Dominant mechanism / competing cause	Clinical evaluation and priority
New ascites or tense abdominal distension	Portal hydrostatic pressure plus renal sodium retention; cardiac, malignant or other ascites remains possible.	Diagnostic paracentesis for new or clinically concerning ascites; assess serum/ascitic albumin and cell count, renal function, volume status.
Fever, pain, confusion or renal deterioration with ascites	Spontaneous bacterial peritonitis (SBP) can present subtly; secondary peritonitis requires another source.	Prompt paracentesis including PMN count/culture; avoid delaying appropriate antibiotics while evaluating infection.
Hematemesis, melena, shock	Ruptured esophageal/gastric varix possible; ulcer or other bleeding source remains possible.	Resuscitation/airway assessment, blood work/type and cross, early vasoactive therapy and infection prophylaxis as indicated; urgent endoscopy.
New disorientation, somnolence or asterixis	Hepatic encephalopathy precipitated by bleeding, infection, constipation, medication, dehydration or electrolytes; other neurologic causes possible.	Protect airway if impaired, check glucose, medication/exposure review, search for precipitant and treat with gut-directed therapy when indicated.
Rising creatinine, oliguria, hyponatremia	True hypovolemia, acute tubular injury, nephrotoxins, HRS-AKI or obstruction; several can coexist.	Early AKI assessment, stop avoidable nephrotoxins, evaluate hemodynamics/infection and urine findings, involve hepatology/nephrology promptly.
Progressive jaundice, coagulopathy, hypoglycemia	Declining hepatocellular synthetic, excretory and metabolic reserve; acute precipitant may be superimposed.	Assess INR/bilirubin trend, renal function, glucose, mental status; evaluate acute-on-chronic deterioration and transplant need.

Differential Diagnosis

Differentiate spontaneous from secondary peritonitis

Secondary bacterial peritonitis should be considered with focal peritoneal signs, polymicrobial infection, very abnormal ascitic chemistry, poor response to appropriate treatment, or radiologic evidence of perforation/abscess. Obtain directed imaging and urgent source-control evaluation when these clues are present. Paracentesis should not be postponed solely because the cirrhotic INR is elevated; assess the full procedural risk instead (Biggins et al., 2021; Damjanovska, 2024; Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

An early differential prevents the wrong treatment

Establish baseline and current creatinine and urine output; assess infection, bleeding, shock, medication toxicity, urine studies and possible obstruction. If resuscitation is clinically indicated, reassess response within 24 hours rather than requiring albumin for two days in every patient. Avoid indiscriminate albumin loading; reassess intravascular volume and oxygenation, and stop albumin if volume overload develops. In established HRS-AKI, specialist-directed terlipressin with albumin may improve kidney function, but the June 2026 U.S. labeling warns of serious or fatal respiratory failure: do not initiate in hypoxia or worsening respiratory symptoms, and do not use during ongoing coronary, peripheral or mesenteric ischemia. The label requires baseline oxygenation assessment and continuous pulse oximetry; do not initiate while SpO2 is below 90%, and discontinue therapy if SpO2 falls below 90% during treatment. Avoid terlipressin in ACLF grade 3. Volume overload increases respiratory risk; patients with serum creatinine above 5 mg/dL are unlikely to benefit. Individualize albumin to avoid overload (Mallinckrodt Hospital Products Inc., 2026; Nadim et al., 2024).

Diagnostic Limitations and Reassessment

Serum ammonia neither establishes the diagnosis nor reliably stages severity (Bajaj et al., 2026; Mukhtar & Khalili, 2019).

Treatment and Management

Portal hypertensive hemorrhage: stabilize and identify the source

Varices form as portal blood is redirected through vulnerable gastroesophageal collaterals. Active variceal hemorrhage can cause shock, renal ischemia and encephalopathy. An elevated INR in cirrhosis does not, by itself, quantify bleeding propensity: procoagulant and anticoagulant factors are both altered, and portal pressure is the immediate driver of variceal rupture. Acute management includes resuscitation, an appropriate transfusion strategy, vasoactive treatment, antimicrobial prophylaxis and urgent endoscopic hemostasis, with rescue portal decompression for selected cases. Dose, procedural timing, transfusion strategy, and antibiotic selection depend on hemodynamics, bleeding severity, comorbidity, and institutional protocols; antibiotic duration should be individualized to infection risk and cirrhosis severity (Baveno VIII Faculty, 2026; Damjanovska, 2024; Tapper et al., 2026; Williams & Gordon-Walker, 2023).

Multiorgan monitoring and longitudinal decisions

• Track trend and context, not a single isolated result: mental status, blood pressure, pulse, stool or emesis blood, fluid balance, urine output, creatinine, sodium, bilirubin, INR, hemoglobin and evidence of infection.
• Evaluate and correct precipitating events before labeling deterioration as inexorable progression of cirrhosis. A new infection or hemorrhage may be the principal reversible driver of encephalopathy and kidney injury.
• Assess nutrition and sarcopenia, medication safety, variceal prevention, appropriate hepatocellular carcinoma surveillance and the need for transplant evaluation. Risk scores complement but do not replace clinical judgment or prompt response to decompensation.

Prevent recurrence after a decompensating event

• After spontaneous bacterial peritonitis: complete the acute treatment and evaluate for secondary antibiotic prophylaxis because recurrence risk is substantial. Selection must weigh local resistance, prior organisms, renal function, allergies, C. difficile risk and transplant plans. Do not automatically extend this to every patient with ascites; primary prophylaxis has different eligibility considerations (Baveno VIII Faculty, 2026; Biggins et al., 2021; Jahagirdar, 2025; Williams & Gordon-Walker, 2023).
• After esophageal variceal hemorrhage: secondary prevention generally combines a nonselective beta blocker, with carvedilol preferred when appropriate, and serial endoscopic variceal ligation. Reduce or hold beta blockers with persistent systolic pressure below 90 mmHg, mean arterial pressure below 65 mmHg, or HRS-AKI; reassess and retitrate after recovery. Rebleeding despite combined therapy, intolerance, contraindications, and selected high-risk presentations change consideration of TIPS. Coordinate hepatology and endoscopy follow-up rather than treating one successful banding as definitive prevention (Baveno VIII Faculty, 2026; Williams & Gordon-Walker, 2023).
• After overt hepatic encephalopathy: address the precipitant and establish a maintenance strategy, lactulose titrated to 2–3 soft bowel movements daily, with rifaximin added when episodes recur on lactulose. Avoid both undertreatment and excessive diarrhea/dehydration, which can provoke further encephalopathy and kidney injury. Review sedatives, constipation, infection, nutrition, support for adherence and caregiver recognition of early cognitive changes (Bajaj et al., 2026; Mukhtar & Khalili, 2019; Tapper et al., 2026; Williams & Gordon-Walker, 2023).

Across complications, reassess transplant candidacy, renal risk, HCC surveillance, vaccinations, nutrition and ability to access medications or urgent reassessment. When considering vasoconstrictors or antibiotic prophylaxis, individualize the choice to oxygenation, volume status, renal function, contraindications, organism resistance and treatment setting (Mallinckrodt Hospital Products Inc., 2026; Nadim et al., 2024; Tapper et al., 2026).

Complications and Red Flags

Match escalation to simultaneous threats

Hypotension with hematemesis or melena requires bleeding resuscitation, type and crossmatch, infection prophylaxis when appropriate and urgent endoscopy; altered mental status requires immediate glucose and airway assessment in parallel. A patient with new ascites and renal deterioration needs prompt diagnostic paracentesis even without fever. Suspected HRS-AKI is a diagnosis reached after appropriate evaluation, not a shortcut that replaces treating hemorrhage or infection. Transplant evaluation should not wait for every reversible precipitant to be resolved when multiple decompensations signal limited reserve.

Clinical Reasoning Priorities

A patient with cirrhosis develops new ascites, dark stools, confusion and falling urine output. First address possible GI hemorrhage and hemodynamic instability; obtain CBC, renal studies and coagulation/liver tests. Perform indicated paracentesis even if fever is absent. Evaluate bleeding, SBP and other infection, medication effects, electrolyte disturbance and renal perfusion. Encephalopathy may be present, but it does not explain melena or oliguria by itself. Decisions about vasoactive treatment, endoscopy, albumin/vasoconstrictor therapy and transplantation depend on the evolving findings rather than on AST/ALT magnitude (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

---

---

References

Bajaj, J. S., Jakab, S. S., Jesudian, A. B., Rahimi, R. S., Duarte-Rojo, A., Chen, P.-H., Wong, R. J., Tapper, E. B., & Tandon, P. (2026). ACG clinical guideline: Hepatic encephalopathy. The American Journal of Gastroenterology, 121(3), 588–618. https://doi.org/10.14309/ajg.0000000000003899

Baveno VIII Faculty. (2026). Baveno VIII—Advancing consensus in portal hypertension. Journal of Hepatology, 85, 993–1018. https://doi.org/10.1016/j.jhep.2026.07.030

Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 74(2), 1014–1048. https://doi.org/10.1002/hep.31884

Damjanovska, S. (2024, July 1). Peri-procedural management of bleeding risk in cirrhosis. American Association for the Study of Liver Diseases. https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/peri-procedural-management-bleeding-risk-cirrhosis

Jahagirdar, V. (2025, May 20). Antibiotics for SBP prophylaxis—Why or why not? American Association for the Study of Liver Diseases. https://www.aasld.org/liver-fellow-network/core-series/why-series/antibiotics-sbp-prophylaxis-why-or-why-not

Mallinckrodt Hospital Products Inc. (2026). Terlivaz (terlipressin) for injection [Prescribing information; revised June 2026, version 7]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354&version=7

Mukhtar, N. A., & Khalili, M. (2019). Liver disease. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 14). McGraw-Hill Education.

Nadim, M. K., Kellum, J. A., Forni, L., Francoz, C., Asrani, S. K., Ostermann, M., Allegretti, A. S., Neyra, J. A., Olson, J. C., Piano, S., VanWagner, L. B., Verna, E. C., Akcan-Arikan, A., Angeli, P., Belcher, J. M., Biggins, S. W., Deep, A., Garcia-Tsao, G., Genyk, Y. S., . . . Durand, F. (2024). Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. Journal of Hepatology, 81(1), 163–183. https://doi.org/10.1016/j.jhep.2024.03.031

Tapper, E. B., Kardashian, A., Debes, J. D., Gripshover, J., Moon, A. M., Kim, J. J., & Lai, J. C. (2026). ACG clinical guideline: Preventive care for patients with cirrhosis. The American Journal of Gastroenterology. Advance online publication. https://doi.org/10.14309/ajg.0000000000004186

Williams, M. J., & Gordon-Walker, T. T. (2023). Hepatology. In I. D. Penman, S. H. Ralston, M. W. J. Strachan, & R. P. Hobson (Eds.), Davidson’s principles and practice of medicine (24th ed., pp. 859–920). Elsevier.